Press release
Bladder Cancer Pipeline Outlook, FDA Approvals, Clinical Trials, and Companies 2024 (Updated)
Key Takeaways from the Bladder Cancer Pipeline Report
* DelveInsight's Bladder Cancer pipeline report depicts a robust space with 80+ active players working to develop 100+ pipeline therapies for Bladder Cancer treatment.
* The leading Bladder Cancer Companies working in the market include UroGen Pharma Ltd., Asieris Pharmaceuticals, G1 Therapeutics, Inc., LintonPharm Co. Ltd., Vaxiion Therapeutics, Merck Sharp & Dohme LLC, CG Oncology, Inc., Ferring Pharmaceuticals, SURGE Therapeutics, Halozyme Therapeutics, ImmunityBio, Inc., AstraZeneca, Spectrum Pharmaceuticals, Inc., enGene, Inc., CicloMed LLC, Protara Therapeutics, Hoffmann-La Roche, Astellas Pharma Global Development, Inc., and Five Prime Therapeutics, Inc., and others.
* Promising Bladder Cancer Therapies in the various stages of development include Atezolizumab, PGV001, VAX014, BCG Vaccine, Oncofid-P-B, Oncofid-P-B, and others.
* May 2024:- Eli Lilly and Company- The main purpose of this study is to learn more about the safety, side effects, and effectiveness of LOXO-435. LOXO-435 may be used to treat cancer of the cells that line the urinary system and other solid tumor cancers that have a change in a particular gene (known as the FGFR3 gene). Participation could last up to 30 months (2.5 years) and possibly longer if the disease does not get worse.
* May 2024- Merck Sharp & Dohme LLC- The purpose of this study is to assess the safety and efficacy of V940 in combination with pembrolizumab (MK-3475) compared to pembrolizumab alone as an adjuvant treatment for participants with pathologic high-risk muscle-invasive urothelial carcinoma (MIUC) after radical resection. The primary study hypothesis is that V940 in combination with pembrolizumab results in a superior disease-free survival (DFS) as assessed by the investigator compared to pembrolizumab alone in participants with high-risk MIUC after radical resection.
* May 2024:- Ferring Pharmaceuticals- ADSTILADRIN Early Utilization and Outcomes in the Real World Setting in the United States. Multi-center, prospective non-interventional study to collect data on the early use of ADSTILADRIN in the US. Data will be collected from participants, caregivers and prescribing physicians in a real-world setting.
Request a sample and discover the recent advances in Bladder Cancer @ Bladder Cancer Pipeline Outlook Report [https://www.delveinsight.com/sample-request/bladder-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Bladder Cancer Overview
Bladder cancer is a disease that usually begins in the cells that line the inside of the bladder. It typically affects people older than 70 and occurs more often in men. Bladder cancer is the fifth most common form of cancer overall and the fourth most common among men. Bladder cancer usually responds well to treatment when diagnosed early. However, people who have been successfully treated for bladder cancer should be monitored afterward. Bladder cancer can return even years later. About 90 percent of bladder cancers begin in the cells on the surface of the bladder's inner lining.
Bladder cancer Emerging Drugs
* UGN-102: UroGen Pharma Ltd.
* APL 1202 : Asieris Pharmaceuticals
* Trilaciclib: G1 Therapeutics, Inc.
* Catumaxomab: LintonPharm Co.,Ltd.
* VAX 014: Vaxiion Therapeutics
Learn more about Bladder Cancer in clinical trials @ Bladder Cancer Drugs [https://www.delveinsight.com/sample-request/bladder-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Bladder Cancer Therapeutics Assessment
There are approx. 80+ Bladder Cancer companies which are developing the Bladder Cancer therapies. The Bladder Cancer Companies which have their Bladder cancer drug candidates in the most advanced stage, i.e. phase III include, UroGen Pharma Ltd.
DelveInsight's Bladder Cancer pipeline report covers around 100+ products under different phases of clinical development like
* Late stage products (Phase III)
* Mid-stage products (Phase II)
* Early-stage product (Phase I) along with the details of
* Pre-clinical and Discovery stage candidates
* Discontinued & Inactive candidates
Discover more about Bladder Cancer in development @ Bladder Cancer Clinical Trials [https://www.delveinsight.com/sample-request/bladder-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Bladder Cancer Companies
UroGen Pharma Ltd., Asieris Pharmaceuticals, G1 Therapeutics, Inc., LintonPharm Co. Ltd., Vaxiion Therapeutics, Merck Sharp & Dohme LLC, CG Oncology, Inc., Ferring Pharmaceuticals, SURGE Therapeutics, Halozyme Therapeutics, ImmunityBio, Inc., AstraZeneca, Spectrum Pharmaceuticals, Inc., enGene, Inc., CicloMed LLC, Protara Therapeutics, Hoffmann-La Roche, Astellas Pharma Global Development, Inc., and Five Prime Therapeutics, Inc., and others
The bladder cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Oral
* Parenteral
* Intravenous
* Subcutaneous
* Topical
Bladder Cancer Products have been categorized under various Molecule types such as
* Monoclonal Antibody
* Peptides
* Polymer
* Small molecule
* Gene therapy
To know more about Bladder Cancer, visit @ Bladder Cancer Segmentation [https://www.delveinsight.com/sample-request/bladder-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Bladder Cancer Pipeline Report
* Coverage- Global
* Bladder Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Bladder Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
* Bladder Cancer Companies- UroGen Pharma Ltd., Asieris Pharmaceuticals, G1 Therapeutics, Inc., LintonPharm Co. Ltd., Vaxiion Therapeutics, Merck Sharp & Dohme LLC, CG Oncology, Inc., Ferring Pharmaceuticals, SURGE Therapeutics, Halozyme Therapeutics, ImmunityBio, Inc., AstraZeneca, Spectrum Pharmaceuticals, Inc., enGene, Inc., CicloMed LLC, Protara Therapeutics, Hoffmann-La Roche, Astellas Pharma Global Development, Inc., and Five Prime Therapeutics, Inc., and others
* Bladder Cancer Therapies- Atezolizumab, PGV001, VAX014, BCG Vaccine, Oncofid-P-B, Oncofid-P-B, and others.
For further information on the Bladder Cancer Pipeline Therapeutics, reach out @ Bladder Cancer Products Development [https://www.delveinsight.com/sample-request/bladder-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Bladder Cancer : Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Late Stage Products (Phase III)
* UGN-102: UroGen Pharma Ltd.
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Trilaciclib: G1 Therapeutics, Inc.
* Early Stage Products (Phase I)
* VAX 014: Vaxiion Therapeutics
* Inactive Products
* Bladder Cancer Key Companies
* Bladder Cancer Key Products
* Bladder Cancer - Unmet Needs
* Bladder Cancer - Market Drivers and Barriers
* Bladder Cancer - Future Perspectives and Conclusion
* Bladder Cancer Analyst Views
* Bladder Cancer Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=bladder-cancer-pipeline-outlook-fda-approvals-clinical-trials-and-companies-2024-updated]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Bladder Cancer Pipeline Outlook, FDA Approvals, Clinical Trials, and Companies 2024 (Updated) here
News-ID: 3487985 • Views: …
More Releases from ABNewswire
Deos Hair Care Launches its New Hair Growing Shampoo and Conditioner
Image: https://www.abnewswire.com/uploads/782c46f2e762751974c37b0afe469f34.png
Deos Hair Care [https://www.deoshaircare.com/] has launched its new Hair Growth Shampoo and Conditioner, formulated to help people struggling with thinning hair and hair loss. Completely free from paraben, sulfate, and aluminum, this luxury, high-performing, healthy product packs the power of strengthening, reinvigorating, and DHT-blocking ingredients, including caffeine, biotin, rosemary oil, keratin, castor seed oil, and panthenol.
Deos Hair Care has named their product lines Adonis and Aphrodite, after the Greek…
Cake Run Celebrates Recognition as Melbourne's Top Cake Delivery Service
A Melbourne cake delivery service known for its wide range of dietary-specific options and dedication to inclusivity has won the community's hearts.
Cake Run [https://cakerun.com.au/], a prominent cake delivery service in Melbourne, has quickly gained recognition as the city's foremost provider of high-quality cakes catering to diverse dietary needs. Founded in 2022, the company has set a new standard in the cake delivery industry, offering a broad array of cakes that…
NMT Auto Service Hosts Free BBQ Event in Oakville
Oakville Auto Repair shop invites community for a day of food, fun, and prizes.
NMT Auto Service [http://www.nmtoakville.com/] is excited to announce a Free BBQ event on June 15, from 10 AM to 4 PM, in Oakville, Ontario. This community appreciation event will feature a variety of attractions, including complimentary burgers and drinks, a live band, and a chance to win a free set of Michelin tires. The free BBQ is…
Schneider Electric Unveils Resi9 Energy Center Retrofit Innovation for Prosumer …
- New intelligent electrical panel secures electrical installations in homes equipped with new energy landscape devices and renewables
- 2024 marks 100 years of circuit breakers in homes, the devices in our electrical panels that protect our homes' electricity
- Prioritizing safety is crucial when adding solar panels, battery back-up, and electric vehicle chargers to homes
Schneider Electric, the leader in the digital transformation of energy management and automation, today launched its Resi9…
More Releases for Bladder
Overactive Bladder (OAB) - Drug Pipeline Landscape, 2022
Overactive bladder (OAB) is a condition in which the bladder muscle contracts too often and causes urinary frequency, urgency, and incontinence. It affects both men and women, but is more common in women.
The causes of overactive bladder include neurological disorders, such as stroke, multiple sclerosis and eak pelvic muscles, diabetes, urinary tract infections, excess consumption of caffeine or alcohol, declining cognitive function due to aging, difficulty walking.
The most common symptoms…
Bladder Cancer Therapeutics Market : How the Bladder Cancer Therapeutics Market …
As per stats released by the World Cancer Research Fund International, around 430,000 new cases of bladder cancer were diagnosed in 2012, with bladder cancer being the ninth-most common cancer. The bladder holds urine before it leaves the body during urination. The disease in which cancerous cells form in the tissues of the bladder is known as bladder cancer.
Download Free PDF Brochure Of This Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/239
There…
Global Bladder Scanners Sales Market Report 2018
This report studies the global Bladder Scanners market status and forecast, categorizes the global Bladder Scanners market size (value & volume) by key players, type, application, and region. This report focuses on the top players in North America, Europe, China, Japan, Southeast Asia India and Other regions (Middle East & Africa, Central & South America).
A bladder scanner is a medical device that utilizes ultrasound to noninvasively measure the amount of…
Bladder Cance rMarket entry and expansion strategies
MarketResearchReports.Biz adds “Global Bladder Cancer Market Share, Size, Trends and Forecast Market Research Report” reports to its database. This report provides a strategic analysis of the Bladder Cancer and the growth estimates for the forecasted period.
Bladder cancer is a rapidly evolving field in which new developments are constantly influencing the market landscape. The Dynamic Market Forecast is designed to help clients stay abreast of the latest news in the bladder…
Bladder Cancer Pharmaceutical and Healthcare Analysis Information
Summary
Bladder cancer occurs in tissues of the urinary bladder. Symptoms include blood or blood clots in the urine, frequent urination, lower back pain on one side of the body and burning during urination. Risk factors for bladder cancer include smoking, exposure to substances such as rubber, certain dyes and textiles, paint, and hairdressing supplies, diet rich in fried meats and fat, old age, sex and color, certain parasitic infections. Treatment…
Bladder Scanners Market Research Report 2011-2023
Browse full table of contents and data tables at : https://www.reportsandmarkets.com/reports/global-bladder-scanners-market-research-report-2011-2023-1476292
Summary
A bladder scanner is a medical device that utilizes ultrasound to noninvasively measure the amount of urine in the bladder or to determine how much urine remains in the bladder after urination as a way to measure residual levels.
Request a sample copy at : https://www.reportsandmarkets.com/sample-request/global-bladder-scanners-market-research-report-2011-2023-1476292
The type of scanner is a niche ultrasound system that provides fast…
